Cytokinetics, Incorporated develops and commercializes muscle-directed cardiovascular medicines, led by MYQORZO® (aficamten), a cardiac myosin inhibitor approved in the U.S., Europe and China for adults with symptomatic obstructive hypertrophic cardiomyopathy. Company news regularly covers MYQORZO clinical data, launch activity, regulatory approvals and analyses from HCM studies including SEQUOIA-HCM, MAPLE-HCM, FOREST-HCM and ACACIA-HCM.
Recurring updates also address Cytokinetics’ pipeline in cardiac muscle dysfunction, including omecamtiv mecarbil for heart failure with severely reduced ejection fraction and ulacamten for heart failure with preserved ejection fraction. Financial releases and corporate announcements include product revenue, operating updates, shareholder voting matters, common stock offerings and other capital-structure developments.
Cytokinetics (CYTK) presented additional aficamten data showing structural and patient-reported benefits in non-obstructive hypertrophic cardiomyopathy, a thickening of heart muscle. In the ACACIA-HCM imaging sub-study, left ventricular mass index and wall thickness fell versus placebo after 36 weeks (p<0.001), without significant changes in fibrosis. At Week 36, the patient-reported overall health score improved 4.0 points more than placebo; benefits declined after withdrawal, with no differences remaining at study end.
In FOREST-HCM, 12 of 410 obstructive-disease patients (2.9%) developed left ventricular ejection fraction, a measure of pumping function, below 50%. Episodes were transient and reversible, with no associated heart failure hospitalizations or deaths. Cytokinetics plans a Q4 2026 supplemental application for non-obstructive disease.
Cytokinetics (CYTK) reported third-quarter 2026 MYQORZO net product revenue of $44.5 million as it advanced commercial expansion and clinical development. Total revenue rose to $47.6 million from $1.9 million a year earlier. Net loss narrowed to $190.1 million, or $1.37 per share, from $306.2 million, or $2.55 per share. Cash, cash equivalents and investments were approximately $1.6 billion, versus $1.7 billion at June 30.
MYQORZO received Canadian and UK authorizations for adults with symptomatic obstructive hypertrophic cardiomyopathy. Following positive Phase 3 ACACIA-HCM results in non-obstructive disease, the company expects a supplemental US application in Q4 2026 and an EU application in early 2027. It expects a UK launch in Q4 2026 and additional country launches in 2027. Full-year guidance remains $860 million–$890 million in combined research, development, selling, general and administrative expenses.
Cytokinetics (CYTK) announced that members of its management team will participate in four investor conferences during November 2026.
Fireside chats are scheduled at Stifel on November 10 in New York, UBS on November 16 and Jefferies on November 17 in London, and Evercore on November 30 in Coral Gables. Live webcasts will be available through the company website, with replays archived for 90 days after each event.
Cytokinetics (CYTK) announced three presentations at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions in Chicago on November 6, 2026.
The meeting is held in collaboration with the American Heart Association Scientific Sessions. Two late-breaking oral presentations address aficamten’s effects on cardiac structure and function in the ACACIA-HCM CMR study and patient-reported health status in nonobstructive hypertrophic cardiomyopathy. A poster covers left ventricular systolic dysfunction during long-term aficamten therapy in obstructive hypertrophic cardiomyopathy, using a FOREST-HCM analysis. No study results were included in the announcement.
Cytokinetics (Nasdaq: CYTK) is scheduled to report its third quarter results on November 4, 2026, at 4:00 PM Eastern Time. Senior management will host a conference call at 4:30 PM Eastern Time to discuss financial results and provide business updates. A simultaneous webcast will be accessible through the company’s website, where an archived replay will remain available for six months.
Cytokinetics (CYTK) granted stock options and restricted stock units to new employees on October 15, 2026, as employment inducements. The awards cover options to purchase 60,465 shares at $63.92 per share and 40,084 restricted stock units, settled in common shares upon vesting, for 29 employees. Options vest over four years and have a 10-year term; restricted stock units vest over three years.
Cytokinetics (Nasdaq: CYTK) received Health Canada approval for MYQORZO to treat adults with symptomatic obstructive hypertrophic cardiomyopathy, a heart-muscle thickening disorder. The authorization covers New York Heart Association class II-III disease and follows approvals in the U.S., China, European Union and United Kingdom.
Approval was supported by the Phase 3 SEQUOIA-HCM trial. After 24 weeks, peak oxygen uptake increased from baseline by 1.76 mL/kg/min with MYQORZO versus 0.0 mL/kg/min with placebo; the adjusted difference was 1.74 mL/kg/min (p=0.000002). Treatment-emergent serious adverse events occurred in 5.6% versus 9.3%, respectively. However, the Canadian product monograph includes a boxed warning for heart failure: MYQORZO can reduce the proportion of blood pumped out of the left ventricle with each beat. Heart ultrasound assessments are required before and during treatment.
Cytokinetics (CYTK) presented additional ACACIA-HCM analyses showing exercise improvements and safety findings for aficamten in patients with non-obstructive hypertrophic cardiomyopathy.
At 36 weeks, aficamten improved a composite exercise score versus placebo (p<0.001). A clinical response in at least three of five domains occurred in 53% versus 13% (p<0.001). A specified peak oxygen uptake improvement occurred in 45% versus 37%, but was not statistically significant (p=0.1). Left ventricular ejection fraction, the proportion of blood pumped out per beat, fell below 50% in 10.5% versus 0.8%. Serious heart failure events occurred in 4.7% versus 1.2%; all aficamten heart failure events occurred during dose titration or before Week 12 and responded to typical medical therapy. Cytokinetics plans to submit a supplemental FDA application in Q4 2026.
Cytokinetics (CYTK) announced four upcoming presentations at the HFSA Annual Scientific Meeting, taking place October 9–12, 2026, in Phoenix.
Two late-breaking presentations on October 12 will cover aficamten results from ACACIA-HCM. Oral presentations on October 10 and 11 will address right ventricular function and pulmonary coupling in SEQUOIA-HCM, and dosing and safety in ACACIA-HCM, respectively.
Cytokinetics (CYTK) has started ASPEN-HCM, an observational study evaluating MYQORZO in adults with symptomatic obstructive hypertrophic cardiomyopathy, a heart-muscle thickening disorder.
Led by the University of California, San Francisco, the prospective, multicenter study will evaluate treatment safety and effectiveness in routine clinical practice across 13 cardiology practices and HCM centers. It aims to enroll approximately 400 patients over an anticipated 12-to-36-month period. Outcomes include changes in heart-pumping function, treatment discontinuations, blood-flow obstruction, functional classification and patient-reported outcomes.
The study will also examine healthcare resource use, hospitalization and procedure rates, cardiac structural changes and treatment patterns. It will investigate potential predictors of treatment response and whether MYQORZO avoids or delays invasive septal reduction therapy.